from2028 Activists Investors Trump Politicians Serenity Citrini Burry Semianalysis Swing Trade Arbitrage Search

$MLTX:NASDAQ · MoonLake Immunotherapeutics - US

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.

More about this company

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Sector: health

Conviction from: NASDAQ

52-week range: 5.9562.75

2 tracked filer(s) hold this · 0 opened, 1 added, 1 trimmed in 30-JUN-2026

Aggregate 13FScore 72 — mean of 2 scored holder(s) · buyers (new/add) avg 63. Higher = the smart money in this name has the better track record.

Filer	13FScore	This quarter	Shares	Value	% of their book
Paul Tudor Jones / Tudor	63	Added +2%	78,240	$1,523,333	0.0%
Steve Cohen / Point72	80	Trimmed -15%	1,158,732	$22,560,512	0.0%

Beyond 13F — activists, insiders, politicians & research

Activist 13D filings daily digest →

Filed	Form	Activist	% of class	Conviction
2026-04-02	SCHEDULE 13D/A	BIOTECHNOLOGY VALUE FUND L P	22.3%	Med	filing

Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-08-17.